Tempus AI has partnered with NYU Langone Health to enhance cancer care through advanced genomic testing and data analysis. This multi-year collaboration, launched recently, aims to improve genetic diagnostics and accelerate the development of new tests at the Perlmutter Cancer Center. The partnership will support ongoing molecular profiling, enabling more personalized treatment options for patients.
Additionally, Tempus is collaborating with Northwestern Medicine to provide nearly all cancer patients access to genetic testing, including early-stage diagnoses. This initiative will equip healthcare providers with a variety of genomic tests, such as tissue testing and liquid biopsy, to help in selecting tailored treatments.
Over the past year, Tempus’ shares have surged by 114.3%, significantly outperforming the industry growth of 4.3% and the S&P 500’s 22% increase in the same timeframe.
